$2.12
4.07% yesterday
Nasdaq, Nov 03, 10:11 pm CET
ISIN
US00972D1054
Symbol
AKBA

Akebia Therapeutics, Inc. Stock price

$2.12
-0.71 25.09% 1M
-0.22 9.40% 6M
+0.22 11.58% YTD
+0.27 14.59% 1Y
+1.83 643.60% 3Y
-0.30 12.40% 5Y
-8.16 79.38% 10Y
-24.58 92.06% 20Y
Nasdaq, Closing price Mon, Nov 03 2025
-0.09 4.07%
ISIN
US00972D1054
Symbol
AKBA
Industry

Key metrics

Basic
Market capitalization
$562.1m
Enterprise Value
$612.3m
Net debt
$50.1m
Cash
$137.3m
Shares outstanding
263.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.8 | 2.4
EV/Sales
3.0 | 2.7
EV/FCF
negative
P/B
19.2
Financial Health
Equity Ratio
-22.3%
Return on Equity
141.1%
ROCE
1.8%
ROIC
-
Debt/Equity
6.4
Financials (TTM | estimate)
Revenue
$203.7m | $230.5m
EBITDA
$22.0m | -
EBIT
$4.0m | $32.6m
Net Income
$-36.5m | $-5.9m
Free Cash Flow
$-2.6m
Growth (TTM | estimate)
Revenue
16.8% | 43.9%
EBITDA
817.1% | -
EBIT
111.9% | 170.5%
Net Income
9.8% | 91.5%
Free Cash Flow
93.5%
Margin (TTM | estimate)
Gross
83.2%
EBITDA
10.8% | -
EBIT
2.0%
Net
-17.9% | -2.6%
Free Cash Flow
-1.3%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
11.2%
Employees
181
Rev per Employee
$880.0k
Show more

Is Akebia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Akebia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
204 204
17% 17%
100%
- Direct Costs 34 34
10% 10%
17%
170 170
18% 18%
83%
- Selling and Administrative Expenses 106 106
6% 6%
52%
- Research and Development Expense 41 41
1% 1%
20%
22 22
817% 817%
11%
- Depreciation and Amortization 18 18
50% 50%
9%
EBIT (Operating Income) EBIT 3.99 3.99
112% 112%
2%
Net Profit -36 -36
10% 10%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about Akebia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akebia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 12 hours ago
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 51,825 shares of Akebia's common stock on October 31, 2025.
Neutral
GlobeNewsWire
5 days ago
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, prior to the open of financial markets.
Neutral
GlobeNewsWire
7 days ago
Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA
More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO John Butler
Employees 181
Founded 2007
Website akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today